For research use only. Not for therapeutic Use.
Hydroxyurea is an antineoplastic chemotherapy drug. It is primarily known for its use in the treatment of the genetic blood disorder, sickle cell anemia, but it is also approved for the treatment of leukemia, skin cancer, and ovarian cancer.</br>Hydroxyurea targets the ribonucleotide reductase essential to DNA synthesis, and arrests the cell cycle at S-phase.
| Catalog Number | A000303 |
| CAS Number | 127-07-1 |
| Synonyms | ci-c04831, nsc32065 |
| Molecular Formula | CH4N2O2 |
| Purity | ≥95% |
| Target | ribonucleoside diphosphate reductase |
| Storage | 3 years -20C powder |
| Reference | Segal JB, Strouse JJ, Beach MC, et al. Hydroxyurea for the Treatment of Sickle Cell Disease. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Feb. (Evidence Reports/Technology Assessments, No. 165.) 1, Introduction. Available from: http://www.ncbi.nlm.nih.gov/books/NBK38503/</span></p> |
